Elliott Targets Bio-Rad as Shares Continue to Struggle 
Berkshire Hathaway Reveals New Stakes in Delta Air Lines and Macy’s Under Greg Abel 
FTC Antitrust Probe Targets Arm Holdings Over Chip Licensing Practices 
Samsung Shares Drop as Labor Union Confirms Planned Strike 
Analog Devices Nears $1.5B Acquisition of AI Chip Firm Empower Semiconductor 
CXMT Forecasts Record Revenue Growth as Global DRAM Prices Surge 
Takeda Hit With $885M Verdict Over Amitiza Generic Drug Delay Scheme 
Honda Shares Jump as Automaker Forecasts Profit Recovery Despite Historic Loss 
Alphabet Raises Record $3.6 Billion in Yen Bonds to Support AI Expansion 
DOJ May Drop Gautam Adani Fraud Charges Amid $10 Billion U.S. Investment Plan 
OpenAI Wins Elon Musk Lawsuit as Jury Rejects Claims Over AI Mission 
Thyssenkrupp to Shut Down Indiana Automotive Plant by March 2026 
TrumpRx Expands Discount Drug Access With 600 Generic Medications 
Warren Buffett and Stephen Curry Charity Dinner Auction Raises $27 Million for Nonprofits 
US-China Trade Talks Sideline Chip Export Controls as Nvidia China Sales Draw Attention 
SEATTLE, Sept. 20, 2016 -- Cascadian Therapeutics (NASDAQ:CASC), a clinical-stage biopharmaceutical company, today announced that Julie Eastland, Chief Financial Officer, will present a corporate overview at the Ladenburg Thalmann 2016 Healthcare Conference. The presentation will take place at 8:30am EDT on Tuesday, September 27, 2016 in New York City.
A live and archived webcast of the presentation will be accessible on the "Events & Presentations" page of the "News & Events" section of Cascadian Therapeutics' website at www.cascadianrx.com.
About Cascadian Therapeutics
Cascadian Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing innovative product candidates for the treatment of cancer. Our lead product candidate, tucatinib, also known as ONT-380, is an orally active and selective small molecule HER2 inhibitor, which has been studied in approximately 200 patients to date. Preliminary results from two ongoing Phase 1b studies of tucatinib in combination showed promising systemic activity, a favorable safety profile and encouraging activity against brain metastases. Cascadian Therapeutics is also conducting a randomized, double-blind, placebo-controlled Phase 2 study called HER2CLIMB. The study is evaluating tucatinib versus placebo in combination with capecitabine and trastuzumab in late stage HER2+ breast cancer patients, with and without brain metastases, who have previously been treated with a taxane, trastuzumab, pertuzumab and T-DM1. This study is expected to enroll 180 patients across approximately 100 clinical sites in the U.S., Canada, and Western Europe. The Company is also developing a cell cycle inhibitor, Chk1, and plans to move the program forward through IND-enabling studies in 2017. For more information, visit www.cascadianrx.com.
Investor Contact: Julie Rathbun Rathbun Communications 206-769-9219 [email protected] Tricia Truehart The Trout Group 646-378-2953 [email protected] Media Contact: Amy Bonanno BMC Communications 646-513-3117 [email protected]
